Jan 9, 2012 9:00 am EST Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Agents for the Treatment of Neurodegenerative Diseases
Dec 19, 2011 9:00 am EST Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease
Sep 22, 2011 9:00 am EDT Lixte Biotechnology Holdings Announces Issuance of U.S. Patent for Lead Anti-Cancer Compound
May 25, 2011 9:00 am EDT Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Mar 2, 2011 10:39 am EST Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
Oct 5, 2010 9:00 am EDT Lixte Biotechnology Holdings, Inc. Announces the Approval of a Collaboration with the National Cancer Institute for Clinical Evaluation of its Lead Anti-Cancer Compound, LB-100.
Jul 2, 2009 9:00 am EDT Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
Oct 20, 2008 9:20 am EDT Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Aug 19, 2008 8:15 am EDT Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Jun 25, 2008 10:36 am EDT Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs